• Nxera Pharma posted revenue of JPY 18.91 billion for the six months ended June 30, up JPY 3.82 billion from the prior corresponding period.
• Operating profit turned to JPY 1.88 billion from an operating loss of JPY 2.76 billion; net profit swung to JPY 1.59 billion from a net loss of JPY 3.14 billion.
• R&D expenses fell JPY 1.47 billion to JPY 6 billion on maturation of several clinical programs; SG&A decreased JPY 612 million to JPY 6.95 billion on cost cuts.
• Cash and cash equivalents slipped JPY 2.62 billion from fiscal year-end to JPY 17.75 billion.
• First-half updates included rising Japan sales of PIVLAZ and QUVIVIQ, South Korea fast-track designations for vamorolone, and milestone payments from AbbVie, Lilly, Neurocrine and the Centessa collaboration.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nxera Pharma Co. Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608070230PRIMZONEFULLFEED1001256493) on August 07, 2026, and is solely responsible for the information contained therein.